Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zymeworks Inc ZYME

Healthcare Biotechnology
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based... see more

Recent & Breaking News (NDAQ:ZYME)

Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022

Business Wire May 26, 2022

Zymeworks' Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal

Business Wire May 20, 2022

ALL BLUE CAPITAL EXPANDS ITS LEADERSHIP TEAM TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS INC.

PR Newswire May 19, 2022

Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results

Business Wire May 4, 2022

ALL BLUE CAPITAL ANNOUNCES LEADERSHIP TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS, INC.

PR Newswire May 3, 2022

Zymeworks Announces Participation in Upcoming Investor Conferences

Business Wire May 2, 2022

Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons

Business Wire April 28, 2022

Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer

Business Wire April 28, 2022

Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire April 27, 2022

Zymeworks to Host First Quarter 2022 Results Conference Call

Business Wire April 19, 2022

Atreca Announces Expansion of Preclinical Pipeline

GlobeNewswire April 5, 2022

Zymeworks Announces Participation in Upcoming Investor Conferences

Business Wire April 1, 2022

Zymeworks Announces Participation in Upcoming Investor Conferences

Business Wire March 3, 2022

Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results

Business Wire February 24, 2022

Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call

Business Wire February 8, 2022

Zymeworks Announces Participation in Upcoming Investor Conferences

Business Wire February 3, 2022

Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Business Wire January 31, 2022

Zymeworks Announces Pricing of $100.0 Million Public Offering

Business Wire January 26, 2022

Zymeworks Announces Proposed Public Offering

Business Wire January 26, 2022

Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022

Business Wire January 19, 2022